Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Causative Variants Linked With Limb Girdle Muscular Dystrophy in an Iranian Population: 6 Novel Variants Publisher Pubmed



Mianesaz H1, 2 ; Ghalamkari S2, 3 ; Salehi M2, 4 ; Behnam M4, 5 ; Hosseinzadeh M2, 6 ; Basiri K7, 8 ; Ghasemi M7, 8 ; Sedghi M6, 7 ; Ansari B8, 9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Human Genetics, Medical School, University of Debrecen, Debrecen, Hungary
  2. 2. Department of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Division of Clinical Genetics, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
  4. 4. Cellular, Molecular and Genetics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Student Research Committee, Semnan University of Medical Science, Semnan, Iran
  6. 6. Medical Genetics Laboratory, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
  7. 7. Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Science, Tehran, Iran
  8. 8. Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran
  9. 9. Isfahan Neuroscience Research Center, ALzahra Research Institute, Isfahan University of Medical Science, Isfahan, Iran

Source: Molecular Genetics and Genomic Medicine Published:2023


Abstract

Background: Limb-girdle muscular dystrophy (LGMD) is a non-syndromic muscular dystrophy caused by variations in the genes involved in muscle structure, function and repair. The heterogeneity in the severity, progression, age of onset, and causative genes makes next-generation sequencing (NGS) a necessary approach for the proper diagnosis of LGMD. Methods: In this article, 26 Iranian patients with LGMD criteria were diagnosed with disease variants in the genes encoding calpain3, dysferlin, sarcoglycans and Laminin α-2. Patients were referred to the hospital with variable distribution of muscle wasting and progressive weakness in the body. The symptoms along with biochemical and EMG tests were suggestive of LGMD; thus the genomic DNA of patients were investigated by whole-exome sequencing including flanking intronic regions. The target genes were explored for the disease-causing variants. Moreover, the consequence of the amino acid alterations on proteins' secondary structure and function was investigated for a better understanding of the pathogenicity of variants. Variants were sorted based on the genomic region, type and clinical significance. Results: In a comprehensive investigation of previous clinical records, 6 variations were determined as novel, including c.1354–2 A > T and c.3169_3172dupCGGC in DYSF, c.568 G > T in SGCD, c.7243 C > T, c.8662_8663 insT and c. 4397G > C in LAMA2. Some of the detected variants were located in functional domains and/or near to the post-translational modification sites, altering or removing highly conserved regions of amino acid sequence. © 2022 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.